Clinical Trial Modernization Act
Summary
Clinical Trial Modernization Act
This bill authorizes a grant program and provides certain exemptions to support the participation of individuals in clinical trials.
Specifically, the bill authorizes a grant program to support outreach, education, and recruitment efforts for clinical trials that may benefit certain underrepresented populations or communities in need, such as rural or tribal areas.
The bill also exempts from anti-kickback laws for federal health care programs (1) remuneration that is offered to cover participants' expenses to participate in clinical trials, (2) the provision of free digital health technologies to support participation of underrepresented populations in clinical trials, and (3) payment for participants' cost-sharing obligations in relation to clinical trials.
Finally, the bill exempts up to $2,000 in remuneration that is received for participating in a clinical trial from income tax.
Timeline
- May 20, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- May 20, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- May 20, 2025Introduced in House
- May 20, 2025Introduced in House
Cosponsors
In the News
- AACI Urges Congress to Pass the Clinical Trial Modernization Act | Newswise - Newswise
- Lobbying Update: $3,180,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
- How CBO Determines Whether to Classify an Activity as Governmental When Estimating Its Budgetary Effects - Congressional Budget Office (.gov)
Contact your representatives about this bill in under 2 minutes.
📬 Contact Your Reps →